​
Summary

MDR device classification determines your medical device’s risk class (I, IIa, IIb, or III) under EU Medical Device Regulation 2017/745, which directly impacts your conformity assessment procedure, notified body requirements, and regulatory obligations. Classification is based on your device’s intended purpose, duration of use, invasiveness, and specific characteristics according to the detailed rules in Annex VIII. Accurate classification is mandatory for CE marking and market access in the European Union.

​
Why is MDR Device Classification Important?

Device classification under the MDR is fundamental to your entire regulatory strategy because it determines the level of regulatory scrutiny, required documentation, and conformity assessment pathway. Higher-risk classifications require more extensive clinical evidence, notified body involvement, and ongoing surveillance obligations. Misclassification can result in regulatory delays, additional costs, or market withdrawal. Your classification also affects your quality management system requirements, post-market surveillance obligations, and the depth of technical documentation required for your technical file.

​
Regulatory Context

Under EU MDR 2017/745, Annex VIII:

  • Classification rules are mandatory and rule-based - no discretionary interpretation
  • Based on intended purpose, invasiveness, duration of use, and body interaction
  • Determines conformity assessment procedure under Annex IX, X, or XI
  • Higher classes require notified body involvement and more extensive documentation

Special attention required for:

  • Software medical devices - apply Rules 11 and specific MDCG 2019-11 guidance
  • Active implantable devices - automatically Class III under Rule 9
  • Devices with medicinal substances - Rule 14 typically results in Class III
  • Nanomaterials - Rule 19 with specific exposure potential assessment

​
Guide

MDR classification follows a systematic rule-based approach using Annex VIII. Start by understanding the fundamental definitions in Chapter 1, particularly duration of use categories: transient (less than 60 minutes), short-term (60 minutes to 30 days), and long-term (more than 30 days).

Apply the implementing rules systematically. Rule 3.1 states that classification is governed by intended purpose. Rule 3.5 is critical - if multiple rules apply, use the strictest rule resulting in higher classification. This means you must evaluate all potentially applicable rules and select the highest classification result.

Start with non-invasive device rules (Rules 1-4). Rule 1 classifies all non-invasive devices as Class I unless other rules apply. Rule 2 addresses devices for channeling or storing body fluids. Rule 3 covers devices that modify biological or chemical composition. Rule 4 applies to devices contacting injured skin or mucous membranes.

Evaluate invasive device rules (Rules 5-8). Rule 5 covers body orifice devices based on duration and connection to active devices. Rules 6-8 address surgically invasive devices with increasing duration and specific anatomical considerations. Pay special attention to devices contacting the central circulatory system or central nervous system, which typically result in Class III.

Consider active device rules (Rules 9-13). Rule 9 covers therapeutic devices that administer energy. Rule 10 addresses diagnostic and monitoring devices. Rule 11 is specifically for software medical devices and requires careful analysis of clinical decision-making impact. Rules 12-13 cover devices that administer substances and other active devices.

Apply special rules (Rules 14-22) when relevant. These cover specific situations like devices incorporating medicinal substances (Rule 14), contraceptive devices (Rule 15), sterilization devices (Rule 16), and nanomaterials (Rule 19). Software devices often require evaluation under Rule 11, which classifies based on the impact of clinical decisions.

Document your classification justification thoroughly. Reference the specific Annex VIII rule(s) applied, explain why other rules don’t apply, and provide rationale for any interpretation. Your justification must be defensible during notified body assessment and regulatory review.

​
Example

​
Complete MDR Classification Document

MDR Classification Document

ID: MDR-CLASS-2024-001

​
Device Duration of Use

Short term - not less than 60 minutes and not more than 30 days.

The CardioWatch Pro is intended for continuous monitoring periods ranging from several hours to multiple days, with typical use cycles of 24-48 hours before requiring charging. The device may be worn continuously for up to 14 days for extended monitoring as prescribed by healthcare providers.

​
Device Classification

Class IIa

​
Device Classification Justification

CardioWatch Pro is classified as Class IIa under EU MDR 2017/745 based on the following analysis of Annex VIII classification rules:

Rule 10 (Active devices intended for diagnosis and monitoring): CardioWatch Pro is an active device intended for monitoring vital physiological processes (heart rate and rhythm). Under Rule 10, active devices intended for monitoring vital physiological parameters are classified as Class IIa, except when “the nature of variations of those parameters is such that it could result in immediate danger to the patient,” which would result in Class IIb classification.

Analysis: While cardiac arrhythmias can be serious, the CardioWatch Pro is intended for monitoring and recording rather than real-time alerting or emergency response. The device does not provide immediate alarms or automated interventions that would place patients in immediate danger if the device malfunctioned. Healthcare providers review recorded data during scheduled appointments or routine monitoring, not for emergency decision-making.

Rule 11 (Software): The device incorporates software that provides information used for monitoring physiological processes. Under Rule 11, software intended to monitor physiological processes is classified as Class IIa, except if intended for monitoring vital physiological parameters where variations could result in immediate danger (Class IIb).

Analysis: The software component monitors heart rate and rhythm but does not make autonomous clinical decisions or provide immediate alerts that could result in immediate danger if incorrect. The software provides information for healthcare provider review rather than direct clinical decision-making.

Other Rules Considered:

  • Rule 1: Not applicable - device is active, not non-invasive passive device
  • Rule 4: Not applicable - device contacts intact skin, not injured skin or mucous membrane
  • Rule 9: Not applicable - device monitors rather than administers therapeutic energy
  • Rule 5: Not applicable - device is not invasive with respect to body orifices

Conclusion: Under Rule 3.5 (strictest rule applies), both applicable rules (Rule 10 and Rule 11) result in Class IIa classification. No rules result in higher classification. Therefore, CardioWatch Pro is classified as Class IIa.

​
Q&A